ArticleOpen access emergency medicine : OAEM2024
Prognostic Impact of Therapeutic Agents for Septic-Associated Disseminated Intravascular Coagulation According to Different Sources of Infection.
Article in Open access emergency medicine : OAEM, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Sepsis can be caused by various infectious sources; however, treatment strategies for secondary disseminated intravascular coagulation (DIC) differ between countries. The Japanese sepsis guidelines recommend the use of two drugs for DIC but do not specify which drugs should be used and under which conditions. No clear reports have compared the outcomes of DIC treatments based on the source of infection. This is the first study to clarify the difference in prognosis by the source of infection and compare the effect of the treatment of choice for DIC on prognosis. Patients and Methods: This single-center, retrospective, nonrandomized cohort study included 411 patients with a confirmed diagnosis of sepsis-associated DIC who were initiated on DIC therapies. Recombinant thrombomodulin (rTM) preparation and antithrombin (AT) replacement therapy were the DIC therapies used. The patients were divided into five groups determined to be the primary source of infection for treatment: intestine-related, biliary tract, respiratory tract, urinary tract, and catheter-related bloodstream infections (CRBSIs). In addition to differences in DIC treatment, we evaluated the following three covariates that may influence mortality, considering the influence of background interactions at the infection source: serum albumin concentration, APACHE-II score, and blood antithrombin activity. A Cox proportional hazards model was used to assess the association between the covariates and compare their effect on 60-day survival. Results: Univariate analysis of the DIC drug choice results showed that survival was statistically significantly higher in the rTM arm for biliary tract infections (P = 0.002) and CRBSI (P = 0.021). However, multivariate analysis with other covariates showed that AT replacement therapy was statistically effective for respiratory tract infections (hazard ratio, 0.353; P = 0.027). Conclusion: Our study showed that the pathogenesis of severe sepsis with DIC differs depending on the source of infection which should be considered when developing treatment strategies. Particularly, the importance of anti-DIC drug selectivity based on the source of infection was confirmed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.